Physician profile
Sarit Blackstein
NPI 1205297520
$10,020.01
in general payments reported to CMS, 2019-2025
24 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,130 · 2022: $894 · 2023: $2,595 · 2024: $2,553 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,733 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,732.61 |
| Education | $262.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,130.62 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $1,098.56 | 2023-2024 | Vtama |
| Abbvie INC. | $870.02 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $776.39 | 2022-2025 | Sotyktu |
| Pfizer INC. | $701.51 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $656.06 | 2021-2025 | |
| Leo Pharma INC. | $547.30 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $486.23 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $442.87 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $425.98 | 2022-2025 | |
| Ucb, INC. | $405.88 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $365.55 | 2021-2025 | Ilumya, Winlevi |
| Incyte Corporation | $187.62 | 2024-2025 | Opzelura |
| Botanix Sb INC | $179.43 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $170.10 | 2024-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $160.61 | 2021-2023 | Klisyri |
| Amgen INC. | $154.65 | 2023 | Otezla |
| Janssen Scientific Affairs, LLC | $99.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $39.75 | 2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.70 | 2021-2022 | |
| Organon LLC | $27.75 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.92 | 2024 | Ycanth |
| Dermira, INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarit Blackstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.